Search Results - "Copalu, W."

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours by Boss, D S, Glen, H, Beijnen, J H, Keesen, M, Morrison, R, Tait, B, Copalu, W, Mazur, A, Wanders, J, O'Brien, J P, Schellens, J H M, Evans, T R J

“…Background: The objectives of this phase I study were to assess the safety and tolerability of E7080 in patients with advanced, refractory solid tumours; to…”
Get full text

Development of a taste-masked granule formulation of sodium phenylbutyrate adapted for paediatric use by Guffon, N, Kibleur, Y, Copalu, W, Tissen, C, Breitkreutz, J

“…Background Sodium phenylbutyrate (NaPB), a treatment for urea cycle disorders, has an extremely unpleasant, bitter taste which can compromise compliance and…”
Get full text

Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole by Devriese, L. A., Mergui-Roelvink, M., Wanders, J., Jenner, A., Edwards, G., Reyderman, L., Copalu, W., Peng, F., Marchetti, S., Beijnen, J. H., Schellens, J. H. M.

“…Summary Purpose To study the influence of repeated oral administration of ketoconazole, a potent CYP3A4 inhibitor, on the plasma pharmacokinetics of eribulin…”
Get full text

Validation of high-performance liquid chromatography–tandem mass spectrometry assays for the quantification of eribulin (E7389) in various biological matrices by Dubbelman, A.C., Rosing, H., Thijssen, B., Lucas, L., Copalu, W., Wanders, J., Schellens, J.H.M., Beijnen, J.H.

“…This paper presents specific and sensitive high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC–MS/MS) assays for the…”
Get full text

PK PD Model of Indisulam and Capecitabine: Interaction Causes Excessive Myelosuppression by Zandvliet, AS, Siegel‐Lakhai, WS, Beijnen, JH, Copalu, W, Etienne‐Grimaldi, M‐C, Milano, G, Schellens, JHM, Huitema, ADR

“…The anticancer agent indisulam was evaluated in a dose‐escalation study in combination with capecitabine. Severe myelotoxicity was observed after multiple…”
Get full text

574 Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole (KET) by Deviese, L, Wanders, J, Jenner, A, Edwards, G, Reyderman, L, Copalu, W, Peng, F, Marchetti, S, Beijnen, J.H.M, Schellens, J.H.M

Get full text

Developing a new formulation of sodium phenylbutyrate by Guffon, Nathalie, Kibleur, Yves, Copalu, William, Tissen, C, Breitkreutz, Joerg

“…Background Sodium phenylbutyrate (NaPB) is used as a treatment for urea cycle disorders (UCD). However, the available, licensed granule form has an extremely…”
Get full text

Eribulin mesylate pharmacokinetics in patients with hepatic impairment by Witteveen, P., Marchetti, S., Mergui-Roelvink, M., Reyderman, L., Copalu, W., Wanders, J., Jenner, A., Edwards, G., Schellens, J. H., Voest, E. E.

“…Abstract only…”
Get full text

A phase I dose finding study of E7080 in patients (pts) with advanced malignancies by Glen, H., Boss, D., Evans, T. R., Roelvink, M., Saro, J. M., Bezodis, P., Copalu, W., Das, A., Crosswell, G., Schellens, J. H.

“…Abstract only 14073 Background: E7080 is a potent inhibitor of the split-kinase family of transmembrane growth factor receptors including Flt-1 and KDR. In…”
Get full text